Prepping for a PrEP Trial (July/August 2009)
Why is it so hard to find young people to participate in HIV-related studies? While trying to find an assistant to help recruit young, gay men for a trial of pre-exposure HIV prophylaxis (PrEP), HIV advocate Keith Green may have stumbled on an answer: homophobia.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Vaginal Washing Increases HIV Infection Risk; Results for Dry Sex Less Clear-Cut (July 30, 2009)
A meta-analysis of data on vaginal practices and HIV infection from ten African cohorts has found that both vaginal washing with soap and wiping the vagina with cloths, tissues or paper were associated with an increased risk of acquiring HIV.
From aidsmap.com
Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study (July 29, 2009)
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show.
From aidsmap.com
Genotypic Test Matches Tropism Test in Predicting Who Benefits From CCR5 Inhibitors (July 28, 2009)
A genotypic test is just as accurate as a more expensive tropism test in determining which treatment-experienced patients are suitable for treatment with the CCR5 inhibitor maraviroc, researchers from the University of British Columbia reported.
From aidsmap.com
Governor "Terminator" Kills AIDS Program (July 28, 2009)
In a "heartless act" Governor Schwarzenegger dismantles California's lifesaving HIV/AIDS prevention, testing, housing and treatment services; deadly cuts will cripple hiv testing and prevention efforts, endanger public health and cost California taxpayers infinitely more in the future.
From AIDS Healthcare Foundation
Hepatitis B Vaccine Scale-Up and Treatment of HIV/HBV Coinfection Present Challenges (July 28, 2009)
Hepatitis B vaccine coverage has increased dramatically in recent years, but some regions still lag behind and collaboration with broader health programmes would aid scale-up, according to a symposium presentation on viral hepatitis.
From aidsmap.com
Increased Risk of HIV Transmission in Serodiscordant Couples Wishing to Conceive (July 27, 2009)
Harm reduction interventions to avoid HIV transmission in heterosexual, serodiscordant couples who wish to have children are urgently needed, particularly in resource-poor settings, according to Sara Brubaker, M.D., M.P.H., of the University of California-San Francisco.
From aidsmap.com
Raltegravir Moves Closer to Approval for First-Line Use in Europe (July 27, 2009)
A European regulatory committee has recommended expanding raltegravir's marketing authorization to include individuals initiating HAART. The recommendation comes days after trial data was presented about the safety and efficacy of the drug in treatment-naive patients.
From aidsmap.com
DREAM Study: Extended Prenatal Antiretroviral Therapy Protects Against Mother-to-Child Transmission of HIV at Low and High CD4 Levels (July 24, 2009)
Antiretroviral therapy administered during pregnancy and breastfeeding reduces the risk of a woman transmitting HIV to her infant to just 2% by the time the child is six months of age -- even without a Cesarean section or formula feeding, according to a retrospective analysis of participants in the Drug Resource Enhancement Against AIDS and Malnutrition (DREAM) program in sub-Saharan Africa.
From aidsmap.com
Low Bone Mineral Density in Botswana PrEP Trial Participants Raises Concerns (July 24, 2009)
Researchers conducting a trial of tenofovir and emtricitabine as pre-exposure prophylaxis (PrEP) in Botswana have found low bone mineral density levels in HIV-uninfected volunteers at enrollment.
From aidsmap.com
Mma Bana Study: Mother-to-Child Transmission Reduced Below 1% in Breastfeeding Mothers Who Receive ART (July 24, 2009)
Antiretroviral therapy during pregnancy and breastfeeding resulted in a mother-to-child transmission rate of less than 1% in a large randomized comparison of two triple-drug combinations in women with CD4 counts above 200 cells/mm3, according to data from the Mma Bana study.
From aidsmap.com
Anal Cancer in Men With HIV Much More Common in Post-HAART Era: Could HPV Vaccination Help? (July 23, 2009)
The annual incidence of anal cancer among people with HIV has continued to increase in recent years and now stands at 128 cases per 100,000, said Nancy Crum-Cianflone of the U.S. Infectious Disease Clinical Research Program. This is nearly 100 times the rate in the general population.
From aidsmap.com
Antiretrovirals and Condoms Will Have More Effect on HIV in South Africa Than Circumcision, Model Finds (July 23, 2009)
In preliminary results from a mathematical model set up by researchers from the British Columbia Centre for Excellence in HIV/AIDS, male circumcision was found to have a considerably lower impact than condom use or antiretroviral therapy coverage on new HIV infection rates and on death rates in men in South Africa.
From aidsmap.com
ART for Mothers Leading to Decline in Child Deaths, KwaZulu Natal Study Finds (July 23, 2009)
A major decrease in the childhood mortality rate in children under the age of two, observed between 2001 and 2006 in northern rural KwaZulu Natal, South Africa, was associated with the rollout of antiretroviral therapy in that region.
From aidsmap.com
Boosted Darunavir Monotherapy Works Well in Two Studies (July 23, 2009)
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies.
From aidsmap.com
Delays in Starting Treatment Common in ART Programs (July 23, 2009)
Late initiation of antiretroviral treatment following diagnosis is contributing to the continuing high death rate among people who present with low CD4+ cell counts in eight sub-Saharan African countries.
From aidsmap.com
Early Tests of Maraviroc as Microbicide Produce Less Activity Than Expected (July 23, 2009)
Preclinical ex-vivo tests of the entry inhibitor drug maraviroc as a possible microbicide have found that the drug only produced a moderate protective effect against HIV: a 50% to 60% inhibition of HIV infection of penile tissue and an 85% inhibition in colorectal tissue, when given at high doses.
From aidsmap.com
Sustained Response to Interferon Improves Fibrosis in HIV/HCV-Coinfected Patients (July 23, 2009)
HIV-infected people who achieve a sustained virological response to hepatitis C treatment using pegylated interferon plus ribavirin may experience regression of fibrosis and even cirrhosis, according to study findings.
From aidsmap.com
Antiretroviral Roll-Out Results in Major TB Decline in South African Study (July 22, 2009)
The roll-out of antiretroviral treatment to cover 90% of eligible people has resulted in a significant decline in new cases of tuberculosis (TB) in a South African township, demonstrating for the first time the potential of antiretroviral treatment to make major inroads into the burden of TB in high prevalence countries.
From aidsmap.com
Redial! (July 22, 2009)
This week's Ryan White and Needle Exchange Funding Action Alerts are still in effect.
In Housing Works AIDS Issues Update, from Housing Works
Africa Stands at a Threshold in HIV Response (July 21, 2009)
Focus on the epicenter of the HIV epidemic in South Africa highlights both significant increases in access to treatment and the millions still in need.
To read PDF, click here.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from International AIDS Society
Biomedical HIV Prevention, Including Microbicides, Vaccines, Circumcision and PrEP (July 21, 2009)
The lesson we have to learn from the trials that have been completed is that we need to do much more fundamental research, on immunologic mechanisms to further development of vaccines and potentially of microbicides.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Global AIDS Coordinator Addresses Obama's Global HIV/AIDS Policy Agenda (July 21, 2009)
"Each government ultimately holds responsibility for the health of its citizens," and U.S. policies in the Obama era would seek to support country programs and encourage more national government buy-in and leadership, said U.S. Global AIDS Coordinator Eric Goosby at IAS 2009. "The end goal is for each country to control its responses both strategically and, eventually, financially," he said.
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
HIV's Silent Dangers Make Early HIV Treatment Critical, Expert Says (July 21, 2009)
A discussion about inflammation, early treatment and universal treatment access -- Wafaa El-Sadr, M.D., M.P.H., United States.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Needle-Exchange Fight Goes Global (July 21, 2009)
Activists expand demands around syringe exchange, calling on Obama to lift ban on international funding.
In Housing Works AIDS Issues Update, from Housing Works
African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial (July 20, 2009)
Race and gender may prove to be a more critical factor than we think in virologic response to HIV medications. In the large HEAT study, which compared two first-line HAART regimens, Kimberly Smith, M.D., M.P.H., et al found that in both study arms, fewer African Americans (versus white patients) and females (versus males) achieved a viral load of less than 50 copies/mL.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
HIV Treatment as Prevention: How Many Lives Could Be Saved? (July 20, 2009)
If every person in sub-Saharan Africa received voluntary, annual HIV testing and started antiretroviral therapy immediately after diagnosis, HIV incidence would drop 95% in 10 years and more than seven million deaths would be averted, according to a theoretical model presented by Reuben Granich, M.D., M.P.H.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
IAS Conference Begins, Report Says Economic Crisis Forcing Africans Living With HIV/AIDS Off Life-Saving Medications (July 20, 2009)
Medecins Sans Frontieres said that a shortage of antiretrovirals in six African nations would cost the lives of thousands and reverse a decade of gains in HIV/AIDS treatment and prevention. Meanwhile, Julio Montaner, president of the International AIDS Society, excoriated leaders of the world's richest nations as IAS 2009 opened. "The silence of the G8 leaders [on HIV/AIDS] is not just pathetic, it is criminal," he said.
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
If We Can't Overcome HIV Stigma and Discrimination, Access to Care Won't Improve in Africa, Advocate Says (July 20, 2009)
"Right now, we're standing in a sinkhole, with regards to HIV and TB [tuberculosis] treatment" in Africa, said HIV/AIDS advocate Paula Akugizibwe in an eloquent, passionate speech at IAS 2009. "Until we do some serious work, and invest money and time on creating human rights sensitization ... and the imperative of governments to fund this right, then everything else we're doing is essentially self-defeating."
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Scientists Warn Against Retrenchment on AIDS (July 19, 2009)
Amidst a lingering global recession and indications that world leaders are retreating on previous commitments to universal access to HIV prevention and treatment, researchers, implementers and community leaders at IAS 2009 warned of dire public health consequences resulting from a retrenchment on the global fight against AIDS.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from International AIDS Society
Syringe Exchange Ban On Way Out? (July 17, 2009)
Key vote today to lift ugly ban; advocates push against potential amendments.
In Housing Works AIDS Issues Update, from Housing Works
Obama's Ugly AIDS Truth (July 1, 2009)
Housing Works CEO Charles King's speech on Obama's AIDS policies rouses conference attendees.
In Housing Works AIDS Issues Update, from Housing Works
The Treatment Timebomb (PDF) (July 2009)
"We can predict many of the changing treatment needs of people living with HIV in the coming decade and they are not compatible with treatments and prices available today," warns this report created for the United Kingdom Parliament. "Maintaining HIV treatment to keep people alive will cripple developing economies, or place unbearable strains on richer countries trying to support them. Action is needed now, to avert crisis later."
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The All Party Parliamentary Group on AIDS
Trans Justice Now! (July 1, 2009)
Hundreds gather in support of transgender rights, target HRA feet-dragging; GENDA update (or lack thereof).
In Housing Works AIDS Issues Update, from Housing Works
Travel Ban on the Way Out (July 1, 2009)
Advocate pressure leads administration to begin lifting HIV travel ban; comments needed to debunk reg's wrong assumptions.
In Housing Works AIDS Issues Update, from Housing Works
Youth Take to the Streets (July 1, 2009)
At 5th Annual Youth Action Institute, participants protest California budget cuts.
In Housing Works AIDS Issues Update, from Housing Works